Migraines can be more than just a headache—they're often a debilitating condition that impacts daily life. For those suffering from chronic or frequent migraines, newer treatment options like Fremanezumab and Galcanezumab offer a targeted approach to prevention. Both drugs are part of a newer class of medications known as CGRP (calcitonin gene-related peptide) inhibitors, designed to reduce the frequency and intensity of migraine attacks.

What Are Fremanezumab and Galcanezumab?

Fremanezumab, sold under the brand name Ajovy, and Galcanezumab, marketed as Emgality, are injectable medications approved by the FDA to prevent migraines. They work by blocking CGRP, a protein that plays a key role in migraine development. By inhibiting CGRP, these treatments help prevent inflammation and the dilation of blood vessels in the brain, which are common causes of migraine pain.

How Are These Medications Administered?

Both medications are self-administered via subcutaneous injection and are available in monthly or quarterly dosing schedules depending on the brand:

  • Fremanezumab (Ajovy): Monthly or quarterly injections
  • Galcanezumab (Emgality): Monthly injections, with a higher starting dose

Effectiveness of Fremanezumab vs. Galcanezumab

Studies show that both treatments significantly reduce the number of migraine days per month. While some users may respond better to one medication over the other, overall effectiveness is similar. Patients often choose based on individual tolerance, insurance coverage, or frequency of dosing.

Side Effects to Be Aware Of

Like all medications, Fremanezumab and Galcanezumab can have side effects. The most common include:

  • Injection site pain or redness
  • Constipation (Galcanezumab)
  • Fatigue or dizziness
  • Allergic reactions in rare cases

These medications are generally well-tolerated, with most users experiencing minimal side effects.

Who Should Consider These Treatments?

Fremanezumab and Galcanezumab are typically prescribed for adults who experience four or more migraine days per month. They’re especially useful for patients who haven’t found relief through oral medications or who suffer from side effects with traditional therapies.

Insurance and Cost Considerations

Cost is often a concern, but many insurance plans now cover CGRP inhibitors. Manufacturer coupons and patient assistance programs can also reduce out-of-pocket expenses. It’s best to consult with a healthcare provider or pharmacist to explore options for affordable access.

Final Thoughts on Fremanezumab and Galcanezumab

Choosing between Fremanezumab and Galcanezumab depends on your individual health history, lifestyle, and how your body responds to treatment. Both options represent significant progress in migraine prevention, giving patients more control over their condition. Speak with your doctor to determine the best option based on your migraine pattern and treatment goals.